An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization
A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS)
Sponsor: Max Health, Subsero Health
This PHASE4 trial investigates Covid19 and is currently ongoing. Max Health, Subsero Health leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
May 2021 — Apr 2023 [monthly]
Recruiting PHASE4
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE4
▶ Show 1 earlier version
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE4
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Max Health, Subsero Health
For direct contact, visit the study record on ClinicalTrials.gov .